# Daichi Fujimoto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daichi-fujimoto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,081 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 35 |
| i10-index | 82 |
| Last Known Institution | Hyogo University |
| OpenAlex ID | https://openalex.org/A5081905843 |
| ORCID iD | 0000-0003-0615-3000 |
| Works | 243 |

## Researcher papers

- [Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study](https://scholariq.org/papers/early-immune-related-adverse-events-and-association-with-outcome-in-advanced-non/)
- [Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor](https://scholariq.org/papers/efficacy-of-osimertinib-plus-bevacizumab-vs-osimertinib-in-patients-with-i-egfr/)
- [“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy](https://scholariq.org/papers/interchangeability-of-pd-l1-immunohistochemistry-assays-a-meta-analysis-of/)
- [Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L](https://scholariq.org/papers/randomized-phase-iii-study-comparing-gefitinib-with-erlotinib-in-patients-with/)
- [Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study](https://scholariq.org/papers/randomized-phase-2-study-of-osimertinib-plus-bevacizumab-versus-osimertinib-for/)
- [Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study](https://scholariq.org/papers/efficacy-and-safety-of-nivolumab-in-previously-treated-patients-with-non-small/)
- [Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy](https://scholariq.org/papers/pseudoprogression-in-previously-treated-patients-with-non-small-cell-lung-cancer/)
- [Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial](https://scholariq.org/papers/nivolumab-for-advanced-non-small-cell-lung-cancer-patients-with-mild-idiopathic/)
- [Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients](https://scholariq.org/papers/alteration-of-pd-l1-expression-and-its-prognostic-impact-after-concurrent/)
- [Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/characteristics-and-prognostic-impact-of-pneumonitis-during-systemic-anti-cancer/)
- [Histologic transformation of epidermal growth factor receptor–mutated lung cancer](https://scholariq.org/papers/histologic-transformation-of-epidermal-growth-factor-receptor-mutated-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Glycosylation and Glycoproteins Research](https://scholariq.org/topics/glycosylation-and-glycoproteins-research/)

## Researcher university

- [Hyogo University](https://scholariq.org/institutions/hyogo-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.